GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SynBiotic SE (XTER:SBX) » Definitions » EBIT

SynBiotic SE (XTER:SBX) EBIT : €-26.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is SynBiotic SE EBIT?

SynBiotic SE's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was €0.00 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was €-26.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. SynBiotic SE's annualized ROC % for the quarter that ended in Dec. 2023 was 0.00%. SynBiotic SE's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 0.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. SynBiotic SE's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -138.47%.


SynBiotic SE EBIT Historical Data

The historical data trend for SynBiotic SE's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynBiotic SE EBIT Chart

SynBiotic SE Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial -0.01 -0.84 -13.31 -26.00 -11.68

SynBiotic SE Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only -0.43 -12.88 -1.29 -24.71 -

Competitive Comparison of SynBiotic SE's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, SynBiotic SE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SynBiotic SE's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SynBiotic SE's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SynBiotic SE's EV-to-EBIT falls into.


;
;

SynBiotic SE EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-26.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SynBiotic SE  (XTER:SBX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

SynBiotic SE's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=0 * ( 1 - 0% )/( (36.29 + 34.044)/ 2 )
=0/35.167
=0.00 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

SynBiotic SE's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (5.416 + max(0.174, 0)) + (4.889 + max(-3.497, 0)) )/ 2 )
=0/( ( 5.59 + 4.889 )/ 2 )
=0/5.2395
=0.00 %

where Working Capital is:

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.306 + 3.348 + 1.358) - (2.028 + 0 + 2.81)
=0.174

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.481 + 2.765 + 0.488) - (2.362 + 0 + 4.869)
=-3.497

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

SynBiotic SE's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-25.998/18.775
=-138.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SynBiotic SE EBIT Related Terms

Thank you for viewing the detailed overview of SynBiotic SE's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


SynBiotic SE Business Description

Traded in Other Exchanges
N/A
Address
Barer Strasse 7, Munich, BY, DEU, 80333
SynBiotic SE is engaged in the development of Phyto-cannabinoids and other herbal compounds concentrated molecules as well as the development of wellness products. The company engages in synthetic production, drug development, cannabinoids, dietary supplements and cosmetic products. Geographical presence in Germany, Austria, UK, Switzerland and Other countries. Majority of its revenue comes from domestic market.
Executives
Daniel Kruse Geschäftsführender Direktor

SynBiotic SE Headlines

No Headlines